The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFRα

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Shen, Yingying ^a   Shi, Xiaoke ^a   Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALLOGRAFT INFLAMMATORY FACTOR 1; BIM PROTEIN; CASPASE 3; CYTOCHROME C; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; REBASTINIB; STAT3 PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL MUTANT; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HYPEREOSINOPHILIC SYNDROME; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CODON; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; MICE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; QUINOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883248427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073059     Document Type: Article

References (38)

1. Chusid MJ, Dale DC, West BC, Wolff SM, (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27.
2. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, et al. (2009) Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15: 368-373.
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
4. Erben P, Gosenca D, Muller MC, Reinhard J, Score J, et al. (2010) Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 95: 738-744.
5. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ, (2007) Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 67: 3759-3766.
6. Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, et al. (2009) FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284: 7719-7732.
7. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program: 461-476.
8. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, et al. (2012) Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26: 162-164.
9. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, et al. (2011) The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 71: 3189-3195.
10. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, et al. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19: 556-568.
11. Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, et al. (2010) The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther 9: 211-223.
12. Shi X, Jin Y, Cheng C, Zhang H, Zou W, et al. (2009) Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 15: 1686-1697.
13. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
14. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, et al. (2004) The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 103: 2802-2805.
15. Wu Y, Chen C, Sun X, Shi X, Jin B, et al. (2012) Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor alpha and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res 18: 1966-1978.
16. Pan J, Xu G, Yeung SC, (2001) Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 86: 4731-4740.
17. Pan J, She M, Xu ZX, Sun L, Yeung SC, (2005) Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 65: 3671-3681.
18. Jin Y, Chen Q, Lu Z, Chen B, Pan J, (2009) Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci 100: 2210-2217.
19. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, et al. (2012) The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149: 1098-1111.
20. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, et al. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325: 1134-1138.
21. Lu Z, Jin Y, Qiu L, Lai Y, Pan J, (2010) Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 290: 182-191.
22. Cools J, Maertens C, Marynen P, (2005) Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Updat 8: 119-129.
23. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, et al. (2006) Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108: 1374-1376.
24. Goldstein JC, Munoz-Pinedo C, Ricci JE, Adams SR, Kelekar A, et al. (2005) Cytochrome c is released in a single step during apoptosis. Cell Death Differ 12: 453-462.
25. Kole AJ, Knight ER, Deshmukh M (2011) Activation of apoptosis by cytoplasmic microinjection of cytochrome c. J Vis Exp.
26. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, et al. (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4: e294.
27. Gordon PM, Fisher DE, (2010) Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem 285: 14109-14114.
28. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395.
29. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, et al. (2005) Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24: 2317-2329.
30. Hubner A, Barrett T, Flavell RA, Davis RJ, (2008) Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30: 415-425.
31. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, et al. (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793.
32. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, et al. (2009) FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23: 845-851.
33. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, et al. (2005) Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 19: 286-287.
34. Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, et al. (2009) A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 64: 913-918.
35. Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, et al. (2009) Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett 273: 70-79.
36. Radujkovic A, Topaly J, Fruehauf S, Zeller WJ, (2006) Combination treatment of imatinib-sensitive and-resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res 26: 2169-2177.
37. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ, (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17: 212-221.
38. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115: 4206-4216.